Acting Chief von Eschenbach Brings Zeal For Imaging To FDA
This article was originally published in The Gray Sheet
Executive Summary
Andrew von Eschenbach's role in supporting the development of imaging and other diagnostic technology as director of the National Cancer Institute could inform his approach to medical device regulatory issues as he takes on the added role of acting FDA commissioner